Voyager Therapeutics (VYGR) AI Stock Analysis

• Market Cap: $168.22M
• Dividend Yield: N/A
• Average Volume (3M): 773.32K
• Price to Earnings (P/E): 5.0
• Beta (1Y): 1.39
• Revenue Growth: -43.75%
• EPS Growth: -8479.41%
• Country: US
• Employees: 172
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.53
• Shares Outstanding: 55,336,445
• 10 Day Avg. Volume: 676,733
• 30 Day Avg. Volume: 773,320
• PEG Ratio: 0.16
• Price to Book (P/B): 3.96
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -15.60
• Enterprise Value/Market Cap: 2.67
• Enterprise Value/Revenue: 0.99
• Enterprise Value/Gross Profit: 13.81
• Enterprise Value/Ebitda: -2.75
• 1Y Price Target: $15.57
• Price Target Upside: 412.17% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 42 Neutral
• Price Target: $3.00 ▼(-1.32%Downside)

Voyager Therapeutics faces significant financial and valuation challenges. Declining revenues and negative profitability measures weigh heavily on its financial performance. Technical analysis provides mixed signals, with bearish momentum from moving averages. The absence of a dividend yield and a negative P/E ratio further impact the valuation score negatively.

Positive Factors

Financial Position

Voyager has $295M in cash and a projected runway into mid-2027, indicating meaningful potential value creation from clinical advancement, partnering activity, and platform validation.

Market Valuation

Analyst views VYGR as undervalued ahead of upcoming catalysts.

Partnership Milestones

VYGR could realize up to $35mm in regulatory and clinical milestones related to the FXN/GBA1 programs.

Negative Factors

Earnings Performance

Net loss per share was ($0.53) vs consensus of ($0.45).

Market Sentiment

The stock has pulled back approximately 43% this year due to macro factors and investor apathy around small/mid-cap biotech.

Stock Price Target

The price target has been reduced from $13 to $12.

Voyager Therapeutics Business Overview & Revenue Model

Company Description

Voyager Therapeutics, Inc. (VYGR) is a biotechnology company focused on developing life-changing gene therapies for patients suffering from severe neurological diseases. The company's core offerings include a pipeline of innovative products targeting conditions such as Parkinson's disease, Huntington's disease, and other rare, debilitating neurological disorders. By leveraging its proprietary adeno-associated virus (AAV) vector platform, Voyager aims to deliver gene therapies that address the underlying genetic causes of these diseases, providing potential long-term therapeutic benefits.

How the Company Makes Money

Voyager Therapeutics makes money primarily through strategic collaborations, licensing agreements, and milestone payments related to its gene therapy programs. The company partners with larger pharmaceutical firms to co-develop and commercialize its therapeutic candidates, which enables it to share in the research and development costs while also receiving upfront payment, milestone payments, and potential royalties on sales. Additionally, Voyager may receive government grants or other funding to support its research initiatives. These partnerships and funding sources are critical to advancing its pipeline and generating revenue before its therapies reach commercialization.

Voyager Therapeutics Financial Statement Overview

Summary

Voyager Therapeutics faces significant financial challenges, including revenue volatility, negative profit margins, and strained cash flow. Despite a stable equity position and manageable leverage, the company's profitability and cash flow sustainability are major concerns.

Income Statement

Voyager Therapeutics has experienced significant revenue volatility, with recent declines from previous highs, reflecting potential challenges in maintaining consistent revenue streams. The TTM Gross Profit Margin is 48.54%, indicating some efficiency in managing production costs, but the Net Profit Margin is negative, highlighting ongoing profitability challenges. The EBIT and EBITDA Margins are also negative, reinforcing the company's struggles to achieve operational profitability.

Balance Sheet

The company's balance sheet shows a relatively stable equity position with a Debt-to-Equity Ratio of 0.15, suggesting manageable leverage levels. The Equity Ratio is robust, at 77.20%, indicating strong equity financing. However, Return on Equity is negative due to persistent net losses, which is a concern for investors seeking returns.

Cash Flow

The company's cash flow situation is strained, with negative Free Cash Flow growth, indicating challenges in generating cash from operations. The Operating Cash Flow to Net Income Ratio is negative, reflecting difficulties in converting income into cash flow. Despite these challenges, there was a significant cash inflow from financing activities in the prior period, which temporarily bolstered liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	66.96M	80.00M	250.01M	40.91M	37.41M	171.13M
Gross Profit	32.51M	80.00M	245.57M	34.72M	-36.37M	62.38M
EBITDA	-97.25M	-78.56M	126.45M	-44.65M	-68.45M	31.20M
Net Income	-84.69M	-65.00M	132.33M	-46.41M	-66.03M	36.74M
Balance Sheet
Total Assets	353.24M	393.05M	351.28M	159.36M	193.85M	261.58M
Cash, Cash Equivalents and Short-Term Investments	236.02M	266.68M	230.88M	118.85M	132.54M	181.14M
Total Debt	42.00M	43.73M	20.29M	23.13M	44.18M	47.61M
Total Liabilities	80.54M	93.29M	114.96M	100.34M	98.80M	107.26M
Stockholders Equity	272.70M	299.76M	236.32M	59.02M	95.06M	154.32M
Cash Flow
Free Cash Flow	-114.01M	-18.83M	74.66M	-15.00M	-55.13M	-108.81M
Operating Cash Flow	-111.97M	-15.31M	77.92M	-12.51M	-53.52M	-96.72M
Investing Cash Flow	42.41M	-94.86M	-141.64M	-7.34M	65.91M	113.00M
Financing Cash Flow	1.24M	114.02M	33.65M	1.11M	612.00K	3.16M

Voyager Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYGR, the sentiment is Negative. The current price of 3.04 is below the 20-day moving average (MA) of 3.18, below the 50-day MA of 3.23, and below the 200-day MA of 4.83, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 45.55 is Neutral, neither overbought nor oversold. The STOCH value of 52.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VYGR.

Voyager Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	59 Neutral	HK$15.37B	5.69	-7.44%	4.08%	11.55%	-28.15%
FHTX	50 Neutral	$285.95M	―	322.49%	―	-30.66%	36.48%
FHTX	50 Neutral	$285.95M	―	322.49%	―	-30.66%	36.48%
FDMT	47 Neutral	$196.42M	―	-32.97%	―	―	―
FDMT	47 Neutral	$196.42M	―	-32.97%	―	―	―
TERN	45 Neutral	$349.35M	―	-32.12%	―	―	10.98%
PRME	43 Neutral	$408.33M	―	-115.21%	―	―	20.58%
VYGR	42 Neutral	$168.22M	5.05	-27.61%	―	-43.75%	-8479.41%
ANNX	38 Underperform	$299.52M	―	-66.13%	―	―	43.21%

Voyager Therapeutics Corporate Events

Voyager Therapeutics Approves Stock Plans at Annual Meeting

At the annual meeting held on June 3, 2025, Voyager Therapeutics‘ stockholders approved the 2025 Stock Incentive Plan and the Amended and Restated 2015 Employee Stock Purchase Plan, both previously adopted by the Board of Directors. Additionally, stockholders elected four Class I directors to serve until the 2028 meeting, approved executive compensation, and ratified Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s governance and operational strategies moving forward.

The most recent analyst rating on (VYGR) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Voyager Therapeutics stock, see the VYGR Stock Forecast page.